Genetic predisposition to neuroleptic malignant syndrome: Implications for antipsychotic therapy

American Journal of PharmacoGenomics

Volumn 3, Issue 2, 2003, Pages 89-95

  Kawanishi, Chiaki ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CARRIER PROTEIN; CYTOCHROME P450 2D6; DANTROLENE; DEBRISOQUINE; DIAZEPAM; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLIZING ENZYME; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR;

DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIPSYCHOTIC AGENTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 0038014083     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200303020-00002     Document Type: Review

References (78)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1989; 279: 1200-5
2. Masellis M, Basile VS, Özdemir V, et al. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry 2000; 47: 252-66
3. Veenstra-VanderWeele J, Anderson GM, Cook Jr EH. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 2000; 410: 165-81
4. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250: 186-200
5. Pacifici GM, Pelkonen O, editors. Interindividual variability in drug metabolism in humans. London: Taylor & Francis, 2001
6. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77: 185-202
7. Ayd FJ. Fatal hyperpyrexia during chlorpromazine therapy. J Clin Exp Psychopath 1956; 17: 189
8. Delay J, Pichot P, Lempiere T, et al. Un neuroleptique majeur non phenothiazinique et non reserpinique, l'haloperidol, dans le traitement des psychoses. Ann Med Psychol 1960; 18: 145-452
9. Delay J, Deniker P, editors. Drug-induced extrapyramidal syndrome. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology: diseases of the basal ganglia. Amsterdam: North-Holland Publishing Company, 1968: 248-66
10. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989; 50: 18-25
11. Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 1999; 22: 151-8
12. Adityanjee, Aderibigbe YA, Mathews T. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 1999; 2: 129-44
13. Tanaka K, Akechi T, Yamazaki M, et al. Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient: a case report. Support Care Cancer 1998; 6: 536-8
14. Russell CS, Lang C, McCambridge M, et al. Neuroleptic malignant syndrome in pregnancy. Obstet Gynecol 2001; 98: 906-8
15. Onose M, Kawanishi C, Onishi H, et al. Neuroleptic malignant syndrome following bone marrow transplantation. Bone Marrow Transplant 2002; 29: 803-4
16. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998; 155: 1113-6
17. Caroff SN, Mann SC, Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann 2000; 30: 314-21
18. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987; 22: 1004-20
19. Kontaxakis VP, Christodoulou GN, Markidis MP, et al. Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam. Acta Psychiatr Scand 1988; 78: 396-8
20. Miyaoka H, Shishikura K, Otsubo T, et al. Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype [letter]. Am J Psychiatry 1997; 154: 882
21. Yamawaki S, Yanagawa K. Possible central effect of dantrolene sodium in neuroleptic malignant syndrome. J Clin Psychopharmacol 1986; 6: 378-9
22. Caroff SN, Mann SC, Keck PE, et al. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychoparmacol 2000; 20: 257-9
23. Nemecek D, Rastogi-Cruz D, Csernansky JG. Atropinism may precipitate neuroleptic malignant syndrome during treatment of clozapine. Am J Psychiatry 1993; 150: 1561
24. Young C. A case of neuroleptic malignant syndrome and serotonin disturbance. J Clin Psychopharmacol 1997; 17: 65-6
25. Nishijima K, Ishiguro T. Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biol Psychiatry 1990; 27: 280-8
26. Iwabuchi K, Amano N, Yokoi S, et al. Two autopsied cases of neuroleptic malignant syndrome with the irreversible brain damage and myogenic muscular atrophy. Shinkei Kenkyu no Shinpo 1989; 33: 674-84
27. Lee S, Merriam A, Kim TS, et al. Cerebellar degeneration in neuroleptic malignant syndrome: neurologic findings and review of the literature concerning heatrelated nervous system injury. J Neurol Neurosurg Psychiatry 1989; 52: 387-91
28. Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001; 18: 632-52
29. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15: 410-7
30. Adnet PJ, Krivosic-Horber RM, Adamantidis MM, et al. The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol Scand 1989; 33: 676-80
31. Portel L, Hilbert G, Gruson D, et al. Malignant hyperthermia and neuroleptic malignant syndrome in a patient during treatment for acute asthma. Acta Anaesthesiol Scand 1999; 43: 107-10
32. Heyland D, Sauve M. Neuroleptic malignant syndrome. CMAJ 1991; 145: 817-9
33. Ames D, Wirshing WC. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome: a possible link [letter]. JAMA 1993; 269: 869
34. Daras M, Kakkouras L, Tuchman AJ, et al. Rhabdomyulysis and hyperthermia after cocaine abuse: a variant of the neuroleptic malignant syndrome? Acta Neurol Scand 1995; 92: 161-5
35. Gurrera R. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999; 156: 169-80
36. Itoh H, Ohtsuka N, Ogita K, et al. Malignant neuroleptic syndrome: its present status in Japan and clinical problems. Folia Psychiatr Neurol Jpn 1977; 31: 565-76
37. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986; 73: 337-47
38. Keck Jr PE, Pope Jr HG, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry 1989; 46: 914-8
39. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 1997; 154: 1156-8
40. Berardi D, Amore M, Keck Jr PE, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 1998; 44: 748-54
41. Caroff SN, Mann SC, McCarthy M, et al. Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol 1998; 18: 349-51
42. Deuschl G, Oepen G, Hermle L. Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 1987; 20: 168-70
43. Otani K, Horiuchi M, Kondo T, et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 1991; 158: 850-3
44. Manor I, Hermesh H, Munitz H, et al. Neuroleptic malignant syndrome with gangliosidosis type II. Biol Psychiatry 1997; 41: 1222-4
45. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull 1988; 24: 25-9
46. Wells AJ, Sommi RW, Crismon L. Neuroleptic malignant syndrome: case report and literature review. Drug lntell Clin Pharm 1988; 22: 475-80
47. Lazarus AL, Moore KE, Spinner NB. Recurrent neuroleptic malignant syndrome associated with inv dup (15) and mental retardation. Clin Genet 1991; 39: 65-7
48. Mahendran R, Winslow M, Lim D. Recurrent neuroleptic malignant syndrome. Aust N Z J Psychiatry 2000; 34: 699-700
49. Ram A, Cao Q, Keck PE, et al. Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. Am J Med Genet 1995; 60: 228-30
50. Suzuki A, Kondo T, Otani K, et al. Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001; 158: 1714-6
51. Thompson J, Thomas N, Singleton A, et al. D2 dopamine receptor gene (DRD2) TaqlA polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479-84
52. 2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol 1998; 16: 33-45
53. Suzuki A, Mihara K, Kondo T, et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000; 10: 335-41
54. Schäfer M, Rujescu D, Giegling I, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene. Am J Psychiatry 2001; 158: 802-4
55. Mihara K, Suzuki A, Kondo T, et al. Relationship between Taq1A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 2001; 105: 271-4
56. Mihara K, Kondo T, Suzuki A, et al. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1 A polymorphism of DRD2 gene. Psychopharmacology (Berl) 2000; 149: 246-50
57. Kishida I, Kawanishi C, Furuno T, et al. Lack of association in Japanese patients between neuroleptic malignant syndrome and the Taql A polymorphism of the dopamine D2 receptor gene. Psychiatric Genet 2003; 13: 55-7
58. Arinami T, Gao M, Hamaguchi H, et al. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6: 577-82
59. Insel TR, Roy BF, Cohen RM, et al. Possible development of the serotonin syndrome in man. Am J Psychiatry 1982; 139: 954-5
60. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13
61. Kawanishi C, Hanihara T, Shimoda Y, et al. Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes. Am J Psychiatry 1998; 155: 1275-7
62. Bertilsson L, Dahl ML, Dalén P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53: 111-22
63. Mayer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-71
64. Bertilsson L, Dahl ML, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylation of debrisoquine [letter]. Lancet 1993; 341: 63
65. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993; 90: 11825-9
66. Dahl M-L, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516-20
67. Bertilsson L, Dahl ML. Polymorphic drug oxidation, relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200-23
68. Roh H-K, Dahl ML, Johansson I, et al. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6: 441-7
69. Nishida Y, Fukuda T, Yamamoto I, et al. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 2000; 10: 567-70
70. Kawanishi C, Shimoda Y, Fujimaki J, et al. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci 1998; 160: 102-4
71. Andreassen OA, MacEwan T, Gulbrandsen AK, et al. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacol 1997; 131: 174-9
72. Ohmori O, Suzuki T, Kojima H, et al. Tardive dyskinesia and debrisoquine 4-hydroxylase genotype in Japanese schizophrenics. Schizophr Res 1998; 32: 107-13
73. Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphisms for drug metabolism and tardive dyskinesia in schizophrenia. Schizophr Res 1998; 32: 101-6
74. Kawanishi C, Furuno T, Onishi H, et al. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatr Genet 2000; 10: 145-7
75. Iwahashi K, Yoshihara E, Nakamura K, et al. CYP2D6 Hhal genotype and the neuroleptic malignant syndrome. Neuropsychobiology 1999; 39: 33-7
76. Otani K, Kaneko S, Fukushima Y, et al. NMS and genetic drug oxidation. Br J Psychiatry 1991; 159: 595-6
77. Miyatake R, Iwahashi K, Matsushita M, et al. No association between the neuroleptic malignant syndrome and mutations in the RYR 1 gene associated malignant hyperthermia. J Neurol Sci 1996; 143: 161-5
78. Kawanishi C, Hanihara T, Maruyama Y. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B. Psychiatr Genet 1997; 7: 127-9